Pasithea Therapeutics Corp Share Price Today: Live Updates & Key Insights

Pasithea Therapeutics Corp share price today is $0.797, up 1.91%. The stock opened at $0.766 against the previous close of $0.7821, with an intraday high of $0.80425 and low of $0.7629.

Pasithea Therapeutics Corp Share Price Chart

Pasithea Therapeutics Corp

us-stock
To Invest in {{usstockname}}
us-stock

Pasithea Therapeutics Corp Share Price Performance

$0.797 0.0191(1.91%) KTTA at 23 Mar 2026 01:54 PM Biotechnology
Lowest Today 0.7629
Highest Today 0.80425
Today’s Open 0.766
Prev. Close 0.7821
52 Week High 2.34
52 Week Low 0.28
Day’s Range: Low 0.7629 High 0.80425
52-Week Range: Low 0.28 High 2.34
1 day return -
1 Week return -4.95
1 month return +1.88
3 month return -32.05
6 month return +10.72
1 year return -36.64
3 year return -91.13
5 year return -98.86
10 year return -

Pasithea Therapeutics Corp Institutional Holdings

Adage Capital Partners Gp LLC 9.09

Squadron Capital Management LLC 9.09

Vivo Capital, LLC 9.09

Longwood Capital Partners LLC 1.95

StemPoint Capital LP 1.54

AdvisorShares Psychedelics ETF 1.46

AdvisorShares Investments, LLC 1.32

Persistent Asset Partners Limited 1.26

Stonepine Capital Management Llc 1.19

Vanguard Group Inc 0.42

Jane Street Group LLC 0.26

Citadel Advisors Llc 0.24

Geode Capital Management, LLC 0.24

Vanguard Institutional Extnd Mkt Idx Tr 0.23

Two Sigma Investments LLC 0.21

Fidelity Extended Market Index 0.18

XTX Topco Ltd 0.15

Virtu Financial LLC 0.11

NT Ext Equity Mkt Idx Fd - L 0.08

UBS Group AG 0.08

Fidelity Series Total Market Index 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.03

Spartan Total Market Index Pool G 0.02

Hurley Capital, LLC 0.02

Tower Research Capital LLC 0.01

Northern Trust Extended Eq Market Idx 0.01

SBI Securities Co Ltd 0.00

Citigroup Inc 0.00

Spartan Extended Market Index Pool F 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Pasithea Therapeutics Corp Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Pasithea Therapeutics Corp Fundamentals

Market Cap 25.09 M

PB Ratio 1.5077

PE Ratio 0.0

Enterprise Value 6.43 M

Total Assets 16.06 M

Volume 205108

Pasithea Therapeutics Corp Company Financials

Annual Revenue FY23:486559 0.5M, FY22:486559 0.5M, FY21:15062 0.0M, FY20:null 0.0M

Annual Profit FY23:null 0.0M, FY22:373364 0.4M, FY21:-2213 -0.0M, FY20:null 0.0M

Annual Net worth FY23:-16031187 -16.0M, FY22:-13056481 -13.1M, FY21:-2174029 -2.2M, FY20:null 0.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-181541 -0.2M, Q2/2025:-161745 -0.2M, Q1/2025:-161707 -0.2M, Q3/2024:null 0.0M, Q2/2024:-162256 -0.2M

Quarterly Net worth Q3/2025:-3037420 -3.0M, Q2/2025:-3716157 -3.7M, Q1/2025:-3563238 -3.6M, Q3/2024:-2999834 -3.0M, Q2/2024:-3866249 -3.9M

About Pasithea Therapeutics Corp & investment objective

Company Information Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Organisation Biotechnology

Employees 4

Industry Biotechnology

CEO Dr. Tiago Reis Marques M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Pasithea Therapeutics Corp FAQs

What is the share price of Pasithea Therapeutics Corp today?

The current share price of Pasithea Therapeutics Corp is $0.797.

Can I buy Pasithea Therapeutics Corp shares in India?

Yes, Indian investors can buy Pasithea Therapeutics Corp shares by opening an international trading and demat account with Motilal Oswal.

How to buy Pasithea Therapeutics Corp shares in India?

You can easily invest in Pasithea Therapeutics Corp shares from India by:

Can I buy fractional shares of Pasithea Therapeutics Corp?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Pasithea Therapeutics Corp?

Pasithea Therapeutics Corp has a market cap of $25.09 M.

In which sector does Pasithea Therapeutics Corp belong?

Pasithea Therapeutics Corp operates in the Biotechnology sector.

What documents are required to invest in Pasithea Therapeutics Corp stocks?

To invest, you typically need:

What is the PE and PB ratio of Pasithea Therapeutics Corp?

The PE ratio of Pasithea Therapeutics Corp is N/A and the PB ratio is 1.51.